All In Biotech

Drug Trial Radar · NCT05889182

A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy

A Phase 3, Randomized, Placebo-Controlled, Double-Blind Study to Evaluate Efficacy and Safety of Upadacitinib in Adult and Adolescent Subjects With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy

Last checked: Nov 19, 2026Latest source record: Nov 13, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingPhase 3. Randomized with 1,328 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

1,328

Planned (sponsor's estimate)

Start

Jun 21, 2023

Primary completion

Aug 2028

Study completion Aug 2028

Sponsor

Lead sponsor
AbbVieAbbVie (ABBV)
Sponsor type
Industry
First posted
Jun 5, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 12 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Hidradenitis suppurativa (HS) is an inflammatory skin disease that causes painful lesions in the axilla (underarm), inguinal (groin) and anogenital (anal/genital) regions. This study will assess how safe and effective upadacitinib is in treating adult and adolescent participants with moderate to severe HS who have failed to respond to or are intolerant of anti-tumor necrosis factor (TNF) therapy. Adverse events and change in disease activity will be assessed. Upadacitinib is an approved drug for ulcerative colitis, atopic dermatitis, rheumatoid arthritis, psoriatic arthritis, and axial spondylarthritis and is being developed for the treatment of HS. This study is "double-blinded", meaning that neither the trial participants nor the study doctors will know who will be given upadacitinib and who will be given placebo. This study is comprised of 3 periods. In Period 1, participants are randomized into 2 groups called treatment arms where each group receives a different treatment. There is a 1 in 2 chance that participants will be assigned to placebo. In Period 2, participants are placed into 6 different groups depending on their placement and results in Period 1. Period 3 is the long-term extension period where participants will continue treatment from Period 2. Approximately 1328 adult and adolescent participants diagnosed with HS will be enrolled in approximately 300 sites worldwide. Participants will receive oral tablets of upadacitinib or placebo once daily for 36 weeks in Period 1 and Period 2. Eligible participants from Period 1 and Period 2 will enter Period 3 and receive oral tablets of upadacitinib or placebo once daily for 68 weeks. Participants will be followed up for approximately 30 days. There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular outpatient visits during the study. The effect of the treatment will be checked by medical assessments, checking for side effects and completing questionnaires.

Conditions

  • Hidradenitis Suppurativa

Interventions

  • UpadacitinibDrug

    Oral Tablets

  • PlaceboDrug

    Oral Tablets

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of Participants Achieving Hidradenitis Suppurative Clinical Response (HiSCR) 50Time frame: Baseline to Week 16
  2. Number of Participants with Adverse Events (AEs)Time frame: Up to Approximately Week 108

Locations

285 sites in 37 countries. Site status is shown where the registry gives one.

  • Cahaba Dermatology and Skin Health Center /ID# 254876

    Birmingham, Alabama

  • Peak Dermatology Aesthetics and Wellness Fountain Hills /ID# 272564

    Fountain Hills, Arizona

  • Medical Dermatology Specialists /ID# 254226

    Phoenix, Arizona

  • Mayo Clinic Hospital Scottsdale /ID# 254388

    Scottsdale, Arizona

  • Banner University Medicine Dermatology /ID# 255853

    Tucson, Arizona

  • Clinical Trials Institute - Northwest Arkansas /ID# 254924

    Fayetteville, Arkansas

  • Burke Pharmaceutical Research /ID# 254238

    Hot Springs, Arkansas

  • Arkansas Research Trials /ID# 254233

    North Little Rock, Arkansas

  • Northwest Arkansas Clinical Trials Center /ID# 254311

    Rogers, Arkansas

  • Private Practice - Dr. Tooraj Raoof /ID# 254374

    Encino, California

  • Marvel Clinical Research /ID# 276228

    Huntington Beach, California

  • Dermatology Research Associates /ID# 254846

    Los Angeles, California

  • Norcal Clinical Research /ID# 274219

    Rocklin, California

  • Integrative Skin Science and Research /ID# 254930

    Sacramento, California

  • University of California Davis Health /ID# 254229

    Sacramento, California

  • Medderm Associates /ID# 253800

    San Diego, California

  • Clinical Trials Research Institute /ID# 254466

    Thousand Oaks, California

  • UConn Health Main /ID# 254507

    Farmington, Connecticut

  • Yale University School of Medicine /ID# 254586

    New Haven, Connecticut

  • Skin Care Research Boca Raton /ID# 253814

    Boca Raton, Florida

  • Apex Clinical Trials /ID# 255756

    Brandon, Florida

  • Florida Academic Dermatology Center /ID# 254011

    Coral Gables, Florida

  • Life Clinical Trials - Coral Springs /ID# 258613

    Coral Springs, Florida

  • Dermatology Associates of the Palm Beaches /ID# 275950

    Delray Beach, Florida

  • Skin Care Research - Hollywood /ID# 254508

    Hollywood, Florida

  • Skin Care Research - Tampa /ID# 256440

    Tampa, Florida

  • Advanced Clinical Research Institute - Tampa /ID# 253746

    Tampa, Florida

  • Avita Clinical Research /ID# 254471

    Tampa, Florida

  • Centricity Research - Columbus /ID# 255470

    Columbus, Georgia

  • Treasure Valley Medical Research /ID# 255208

    Boise, Idaho

  • Illinois Dermatology Institute - Chicago Loop Office /ID# 254372

    Chicago, Illinois

  • Northwestern Medicine - Northwestern Memorial Hospital /ID# 254503

    Chicago, Illinois

  • NorthShore University HealthSystem - Skokie /ID# 254389

    Skokie, Illinois

  • Dawes Fretzin /ID# 254390

    Indianapolis, Indiana

  • Options Research Group /ID# 254537

    West Lafayette, Indiana

  • U.S. Dermatology Partners Leawood /ID# 255838

    Leawood, Kansas

  • Equity Medical /ID# 271140

    Bowling Green, Kentucky

  • Massachusetts General Hospital /ID# 261093

    Boston, Massachusetts

  • Beth Israel Deaconess Medical Center /ID# 253811

    Boston, Massachusetts

  • Beacon Clinical Research, LLC /ID# 254419

    Quincy, Massachusetts

Showing 40 of 285 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.